Effect of body mass index on diabetogenesis factors at a fixed fasting plasma glucose level

Jiunn-Diann Lin¹, Chun-Hsien Hsu², Chung-Ze Wu¹, An-Tsz Hsieh¹, Chang-Hsun Hsieh³, Yao-Jen Liang⁴, Yen-Lin Chen⁵, Dee Pei⁶, Jin-Biou Chang⁷*

1 Division of Endocrinology, Department of Internal Medicine, Shuang Ho Hospital, Division of Endocrinology and Metabolism, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC, 2 Department of Family Medicine, Cardinal Tien Hospital, Fu Jen Catholic University School of Medicine, New Taipei City, Taiwan, ROC, 3 Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical School, Taipei, Taiwan, ROC, 4 Department of Life Science, Fu Jen Catholic University, New Taipei City, Taiwan, ROC, 5 Department of Pathology, Cardinal Tien Hospital, Fu Jen Catholic University School of Medicine, New Taipei City, Taiwan, ROC, 6 Department of Internal Medicine, Cardinal Tien Hospital, Fu Jen Catholic University, New Taipei City, Taiwan, ROC, 7 Department of Pathology, National Defense Medical Center, Division of Clinical Pathology, Tri-Service General Hospital, Taipei, Taiwan, ROC

* papersudy@yahoo.com.tw

Abstract

Aim
The present study evaluated the relative influence of body mass index (BMI) on insulin resistance (IR), first-phase insulin secretion (FPIS), second-phase insulin secretion (SPIS), and glucose effectiveness (GE) at a fixed fasting plasma glucose level in an older ethnic Chinese population.

Methods
In total, 265 individuals aged 60 years with a fasting plasma glucose level of 5.56 mmol/L were enrolled. Participants had BMIs of 20.0–34.2 kg/m². IR, FPIS, SPIS, and GE were estimated using our previously developed equations. Pearson correlation analysis was conducted to assess the correlations between the four diabetogenesis factors and BMI. A general linear model was used to determine the differences in the percentage of change among the four factor slopes against BMI.

Results
Significant correlations were observed between BMI and FPIS, SPIS, IR, and GE in both women and men, which were higher than those reported previously. In men, BMI had the most profound effect on SPIS, followed by IR, FPIS, and GE, whereas in women, the order was slightly different: IR, followed by FPIS, SPIS, and GE. Significant differences were observed among all these slopes, except for the slopes between FPIS and SPIS in women (p = 0.856) and IR and FPIS in men (p = 0.258).
Conclusions
The contribution of obesity to all diabetes factors, except GE, was higher than that reported previously. BMI had the most profound effect on insulin secretion in men and on IR in women in this 60-year-old cohort, suggesting that lifestyle modifications for obesity reduction in women remain the most important method for improving glucose metabolism and preventing future type 2 diabetes mellitus.

Introduction
Increased insulin resistance (IR) and deteriorated insulin secretion (ISEC) are considered to be the main mechanisms in type 2 diabetes mellitus (T2DM) development [1]. Evidence has indicated that increased β-cell function maintains the glucose equilibrium in individuals with increased IR [2]. However, overt diabetes eventually develops after the failure of β-cell secretion compensation [1, 2]. Even in the stage of clinically evident diabetes, satisfactory glycemic control can be maintained through lifestyle modifications and medication use, which can improve both IR and β-cell function. However, ISEC consists of two phases: first-phase insulin secretion (FPIS) and second-phase insulin secretion (SPIS) [3, 4]. No direct evidence has supported the aforementioned observation because FPIS disappears early in the prediabetes stage; therefore, SPIS must be responsible for glucose control under oral medications [5].

Glucose clearance from the circulatory system to the muscles, liver, and fat tissues occurs through two pathways: insulin- and non-insulin-mediated glucose uptake. Non-insulin-mediated glucose uptake is also referred to as glucose effectiveness (GE), which represents the ability of glucose to increase its own cellular uptake and restrain its endogenous hepatic output under basal insulin levels. Best et al. reported that GE accounts for 66% of glucose metabolism in healthy individuals but provides 99% of glucose metabolism in patients with T2DM due to high IR and severe insulin deficiency [6]. Therefore, the deterioration of GE has been argued to play a significant role in the occurrence of T2DM [7]. However, very few studies to date have focused on the importance of GE [6]. Therefore, in this study we proposed that IR, GE, FPIS, and SPIS are the four most important factors for diabetes development and control, referred to as diabetogenesis factors (DFs).

Obesity is positively related to high IR and contributes to high β-cell function [8–10]. This increased β-cell mass and resulting increased ISEC might be because of the compensatory reaction to high IR [11, 12]. This aspect of diabetes pathophysiology has been studied quite extensively. However, the effects of obesity on GE or different ISEC stages remain undetermined. For example, Lopez et al. reported that GE deteriorates as body mass index (BMI) increases in nondiabetic individuals, whereas Healy et al. reported contrasting findings [13, 14].

The national health insurance policy in Taiwan has caused a continuous increase in the average life expectancy. Officially, Taiwan became an aging society in 2014, with 11.7% of the population aged more than 65 years [15], which has resulted in a simultaneous rise in T2DM prevalence. Therefore, understanding T2DM pathophysiology is increasingly important.

In the present study, IR, FPIS, SPIS, and GE were examined in the same individuals to evaluate the effects of BMI on the four DFs in the older population. Age and blood glucose levels also affect these four DFs; therefore, we only enrolled individuals with the same age (60 years) and fasting plasma glucose (FPG) level (5.56 mmol/L) to investigate the actual relationships.
Materials and methods

2.1. Ethics

The subjects of the current study were enrolled from the data bank of Meei-Jaw (MJ) Health Screening Centers and Cardinal Tien Hospital data access center between 1999 and 2008. All study subjects were anonymous, and informed consent was obtained prior to participation. These data do not contain potentially identifying or sensitive patient information, data are not owned by a third-party organization. The study proposal was reviewed and approved by the institutional review board of MJ Health Screening Center joint of Cardinal Tien Hospital before the study began. The contact information for the Cardinal Tien Hospital Data Access Committee is +88622219331.

2.2. Participants

The data on the individuals enrolled in the current study were obtained from the databank of the Meei-Jaw (MJ) Health Screening Center for 1999-2008. All study participants remained anonymous, and informed consent was obtained prior to participation. The study proposal was reviewed and approved by the Institutional Review Board of MJ Health Screening Center before the study began. In total, 265 individuals with the same FPG level (5.56 mmol/L) and age (60 years) were enrolled to eliminate the profound effects of age and glucose metabolism. Under these criteria, BMI ranged from 20.0 to 34.2 kg/m². The participants had no other significant diseases, no history of diabetes or diabetic ketoacidosis, and did not use any medication known to influence insulin sensitivity or β-cell function (including oral antihyperglycemic agents) during the study period. BMI was calculated as body weight (kg)/height (m²). Waist circumference (WC) was measured horizontally at the level of the natural waist, which was identified as the level at the hollow molding of a laterally concave trunk. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured in the right arm of seated individuals by using a standard mercury sphygmomanometer. Blood samples were drawn from the antecubital vein for biochemical analysis.

2.3. Calculations of IR, FPIS, SPIS, and GE

IR, FPIS, SPIS, and GE were estimated using our previously developed equations, listed as follows:

\[
IR = (1.439 + 0.018 \times \text{sex} - 0.003 \times \text{age} + 0.029 \times \text{BMI} - 0.001 \times \text{SBP} + 0.006 \times \text{DBP} + 0.049 \times \text{TG} - 0.046 \times \text{HDL-C} - 0.016 \times \text{FPG}) \times 10^{3.333} \quad [16];
\]

\[
\log(\text{FPIS}) = 1.477 - 0.119 \times \text{FPG} + 0.079 \times \text{BMI} - 0.523 \times \text{HDL-C} \quad [17];
\]

\[
\log(\text{SPIS}) = -2.400 - 0.088 \times \text{FPG} + 0.072 \times \text{BMI} \quad [18];
\]

\[
\text{GE} = (29.196 - 0.103 \times \text{age} - 2.722 \times \text{TG} - 0.592 \times \text{FPG}) \times 10^{-3} \quad [19], \text{where HDL-C and TG represent high-density lipoprotein cholesterol and triglycerides, respectively.}
\]

2.4. Laboratory evaluation

After 10-hour overnight fasting, blood samples were collected from each individual for further analysis. The plasma was separated from the whole blood within 1 hour and stored at -70°C. FPG and plasma lipid levels were measured subsequently. The glucose oxidase method (YSI 203 glucose analyzer; Scientific Division, Yellow Springs Instruments, Yellow Springs, OH, USA) was used to determine FPG levels. The dry, multilayer analytical slide method with the
Fuji Dri-Chem 3000 analyzer (Fuji Photo Film, Minato-Ku, Tokyo, Japan) was used to determine total cholesterol and triglyceride (TG) levels. An enzymatic cholesterol assay following dextran sulfate precipitation was used to determine serum HDL-C and low-density lipoprotein cholesterol (LDL-C) levels.

2.5. Statistical analysis

Data are represented as means ± standard deviations. The Student t test was used to evaluate the differences of continuous data between men and women. One-way analysis of variance was used to assess differences in the demographic data, clinical parameters, and DFs among the normal, overweight, and obese groups. The Bonferroni test was used for post hoc analysis. The correlations between the BMI and DFs were evaluated by Pearson correlation analysis. Because the units and scales for these four lines were different, it was difficult to construct all four slopes in one figure. To resolve this problem, we transformed the absolute units into relative units, which represent the percentage of changes in that particular DF, rather than plotting each parameter against the BMI using the original units (e.g., μU/min for FPIS). For example, the lowest and highest values of FPIS (6.06 and 899.10 μU/min, respectively) were regarded as 0% and 100%, respectively. Notably, this transformation did not change the r values of each slope. Other FPIS values were calculated using the following equation:

Percentage of changes in the FPIS value = [(899.1 –the value)/(899.1–6.06)]/100

Similar methods were used to assess the slopes between BMI and IR, GE, and SPIS to compare the changes in the data across the same range of FPG levels. A general linear model was used to determine the differences among the four slopes against the BMI. All statistical tests were two-sided, and p < 0.05 was considered statistically significant. Statistical analysis was performed using SPSS 10.0 for Windows (SPSS, Chicago, IL, USA).

Results

In total, 122 men and 143 women were enrolled in this study. Table 1 presents the demographic characteristics, biochemical data, and DFs. Notably, men had higher WC and higher FPIS but lower HDL-C levels than women.

|                      | Women | Men  | p value |
|----------------------|-------|------|---------|
| N                    | 143   | 122  |         |
| Body mass index (kg/m²) | 23.9 ± 2.5 | 23.9 ± 2.3 | 1.000   |
| Waist circumference (cm) | 75.7 ± 6.7 | 84.1 ± 7.8 | <0.001  |
| Body fat (%) | 32.3 ± 4.8 | 22.4 ± 4.6 | <0.001  |
| SBP (mmHg) | 128.6 ± 21.6 | 126.1 ± 16.9 | 0.516   |
| DBP (mmHg) | 75.0 ± 12.0 | 76.6 ± 11.7 | 0.443   |
| Triglyceride (mmol/L) | 1.4 ± 0.8 | 1.4 ± 0.7 | 0.503   |
| HDL-cholesterol (mmol/L) | 1.6 ± 0.3 | 1.3 ± 0.3 | <0.001  |
| Total cholesterol (mmol/L) | 5.6 ± 0.9 | 5.2 ± 1.0 | 0.002   |
| FPIS (μU/min) | 98.9 ± 82.1 | 128.4 ± 85.4 | 0.004   |
| SPIS (pmol/mmol) | 0.075 ± 0.041 | 0.074 ± 0.033 | 0.803   |
| IR (10⁻⁴ min⁻¹ pmol⁻¹ L⁻¹) | 3.68 ± 0.02 | 3.69 ± 0.02 | 0.535   |
| GE (10⁻² dL min⁻¹ kg⁻¹) | 0.016 ± 0.002 | 0.015 ± 0.0022 | 0.509   |

SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; FPIS, first phase insulin secretion; SPIS, second phase insulin secretion; IR, insulin resistance; GE, glucose effectiveness. Data are presented as mean ± SD.

https://doi.org/10.1371/journal.pone.0189115.t001
Table 2 shows the changes in the studied parameters in normal, overweight, and obese groups. The obese group had the highest WC, IR, FPIS, and SPIS. The overweight group had higher WC, FPIS, SPIS, and IR than the normal group. However, obese women had higher TG but lower HDL-C levels and GE than normal women.

Table 2. Comparison of the demographic characteristics and indices of glucose metabolism in different groups.

|            | Normal group | Overweight group | Obese group |
|------------|--------------|------------------|-------------|
| Women      |              |                  |             |
| N          | 80           | 45               | 18          |
| BMI (kg/m²) | 22.2 ± 1.2²,³ | 25.3 ± 0.8¹,³    | 28.5 ± 1.8¹,² |
| Waist circumference (cm) | 72.2 ± 4.7²,³ | 77.6 ± 4.1¹,³    | 86.5 ± 6.2¹,² |
| SBP (mmHg) | 126.5 ± 21.0 | 129.2 ± 19.7     | 131.1 ± 16.1 |
| DBP (mmHg) | 74.2 ± 12.4  | 76.2 ± 12.1      | 75.6 ± 10.5  |
| Triglyceride (mmol/L) | 1.2 ± 0.7³ | 1.5 ± 0.8        | 1.7 ± 0.8¹ |
| HDL-cholesterol (mmol/L) | 1.6 ± 0.3³ | 1.6 ± 0.4        | 1.3 ± 0.2¹ |
| Total cholesterol (mmol/L) | 5.6 ± 0.9 | 5.6 ± 0.7        | 5.5 ± 1.1   |
| FPIS (µU/min) | 58.6 ± 27.1²,³ | 106.8 ± 5.0¹,³   | 257.9 ± 108.²¹,² |
| SPIS (pmol/mmol) | 0.052 ± 0.010²,³ | 0.086 ± 0.012¹,³ | 0.153 ± 0.061¹,² |
| IR (10⁻⁴ min⁻¹ pmol⁻¹ L⁻¹) | 3.67 ± 0.02²,³ | 3.69 ± 0.02³ | 3.71 ± 0.01² |
| GE (10⁻² dL min⁻¹ kg⁻¹) | 0.016 ± 0.002³ | 0.016 ± 0.002 | 0.015 ± 0.002² |

Men

|            | 64           | 44               | 14          |
|------------|--------------|------------------|-------------|
| BMI (kg/m²) | 22.2 ± 1.1²,³ | 25.1 ± 0.8¹,³    | 28.5 ± 1.2¹,² |
| Waist circumference (cm) | 79.2 ± 4.9²,³ | 87.3 ± 5.5¹,³    | 96.5 ± 5.7¹,² |
| SBP (mmHg) | 123.4 ± 15.8 | 130.3 ± 17.9     | 125.9 ± 17.1 |
| DBP (mmHg) | 74.9 ± 10.5  | 79.3 ± 13.3      | 76.2 ± 10.5  |
| Triglyceride (mmol/L) | 1.3 ± 0.7 | 1.6 ± 0.7        | 1.4 ± 0.6   |
| HDL-cholesterol (mmol/L) | 1.3 ± 0.3 | 1.2 ± 0.4        | 1.3 ± 0.3   |
| Total cholesterol (mmol/L) | 5.2 ± 1.0 | 5.2 ± 0.9        | 5.6 ± 1.1   |
| FPIS (µU/min) | 79.1 ± 30.4²,³ | 153.2 ± 60.8¹,³  | 257.9 ± 117.0¹,² |
| SPIS (pmol/mmol) | 0.052 ± 0.009²,³ | 0.083 ± 0.011¹,³ | 0.148 ± 0.030¹,² |
| IR (10⁻⁴ min⁻¹ pmol⁻¹ L⁻¹) | 3.67 ± 0.02²,³ | 3.69 ± 0.01³ | 3.71 ± 0.01² |
| GE (10⁻² dL min⁻¹ kg⁻¹) | 0.016 ± 0.002³ | 0.015 ± 0.002 | 0.016 ± 0.002² |

Normal = 18.5 ≤ BMI < 24; overweight = 24 ≤ BMI < 27; obese = BMI ≥ 27. BMI = body mass index; HDL = high-density lipoprotein; FPIS = first-phase insulin secretion; SPIS = second-phase insulin secretion; IR = insulin resistance; GE = glucose effectiveness. Data are presented as means ± SDs. ¹p < 0.05 to normal group; ²p < 0.05 to overweight group; ³p < 0.05 to obese group.

https://doi.org/10.1371/journal.pone.0189115.t002

Table 3. The correlations between the body mass index and diabetes factors.

|          | FPIS       | SPIS       | IR         | GE         |
|----------|------------|------------|------------|------------|
| Women    | 0.813      | 0.926      | 0.730      | -0.203     |
| Men      | 0.795      | 0.966      | 0.780      | -0.204     |

FPIS = first-phase insulin secretion; SPIS = second-phase insulin secretion; IR = insulin resistance; and GE = glucose effectiveness. Data are presented as r values; all p < 0.001.

https://doi.org/10.1371/journal.pone.0189115.t003
respectively. As mentioned previously, these slopes were obtained by transforming the absolute units into relative units (% changes) before comparison. In men, BMI had the most profound effect on SPIS, followed by IR, FPIS, and GE, whereas in women, the order was slightly different: IR, followed by FPIS, SPIS, and GE. However, a significant difference was observed between all these slopes, except for the slopes between FPIS and SPIS in women (p = 0.856) and IR and FPIS in men (p = 0.258). The relevant data (1061012-MJ-BMI) is shown in S1 File. All relevant results are within the paper and its Supporting Information files.

**Discussion**

Age and FPG levels affect all DFs; therefore, they were included as confounding factors. The present study specifically enrolled individuals with the same age (60 years) and FPG level (5.56 mmol/L) to avoid these effects. Therefore, we evaluated the pure effect of BMI on these four DFs. Our results demonstrate that IR, FPIS, and SPIS are highly correlated with BMI compared with the findings of previous studies, suggesting that the contribution of obesity to FPIS, SPIS, and IR is more important than generally expected. In addition, the present results demonstrate that the contributions of the four DFs differ between women and men. In women, IR was most strongly correlated with BMI, followed by FPIS, SPIS, and GE. However, the order changed to SPIS, IR, FPIS, and GE in men. Our results not only improve understanding of T2DM pathophysiology but also can be applied in the clinical prevention and management of T2DM.

The study individuals with the same FPG level were categorized into normal, overweight, and obese groups. In addition, the clinical parameters and DFs were compared among the
three groups. The results indicate that obesity has a significant influence on TG and HDL-C levels in women but not in men, which can be attributed to the differences in the basic sex hormone effects on the regulation of lipid metabolism [20, 21] and the diversity in insulin-mediated free fatty acid and TG metabolisms between women and men [22]. Furthermore, FPIS, SPIS, and IR increased markedly from the normal to overweight groups and further increased from the overweight to obese groups (Table 2). However, GE did not change significantly in men and decreased slightly from normal to obese women, indicating that the pure effect of BMI on GE is minor in both women and men (Table 1).

Increasing evidence has shown that obesity is the core contributor to IR [23–25]. BMI reduction through lifestyle modifications can improve IR, which could reduce the incidence of T2DM [23–25]. For the established T2DM individuals, improved IR is equivalent to appropriate glucose control [23–25]. The relationship between BMI and IR has been studied extensively in different ethnic groups. However, the range of r values was approximately 0.4–0.59 [9, 26–28]. In the present study, the r value obtained using our previously derived equations was the highest (r = 0.747, Table 3) compared with other studies [16]. This minor discrepancy in results might be due to differences in genetic background, sample size, glucose levels, and inclusion criteria, as well as BMI. The BMIs reported in previous studies are higher than that reported in the present study (27–28 kg/m² vs. 24.2 kg/m²). Notably, no previous studies have used a cohort with the same age and FPG level. We believed that by fixing the range of these two confounders, the true effect of BMI could be elucidated.

Obese individuals have higher β-cell function because they have higher cell mass than lean individuals [27,29,30]. Hanley et al. conducted the frequently sampled intravenous glucose tolerance test (FSIGT) for FPIS measurement and reported that FPIS is only weakly associated
with BMI \( (r = 0.14) \) in nondiabetic individuals (age: 53–54 years, BMI: 28–30) [27]. Another study used clamps to measure SPIS and revealed the same finding that BMI is correlated with both FPIS and SPIS \( (r = 0.28 \text{ and } 0.41, \text{ respectively}) \) in Caucasians without diabetes [28]. However, this study was conducted on a younger cohort (BMI: 26–27, age 42–48 years). In accordance with these studies, our findings demonstrate that FPIS is strongly correlated with BMI \( (r = 0.796, p < 0.001) \).

The importance of SPIS remains unclear. The relative importance of ISEC and IR differs between Caucasians and Asians [31]. For many Asian patients with diabetes, glucose can be controlled satisfactorily for many years through oral hypoglycemic drugs. Because FPIS disappears early in the prediabetes stage, it is reasonable to postulate that SPIS must be the most important cause of glucose control before insulin injection. The present study successfully demonstrates that, similar to FPIS, SPIS is correlated with BMI \( (r = 0.949, p < 0.001) \). This relationship can be easily explained by the compensation ability of \( \beta \)-cells in response to increasing IR [8, 9, 30, 32]. Notably, the \( r \) values in this study were also higher than those reported in previous studies (0.01–0.1). Furthermore, old age, a highly homogeneous study cohort, and a lower BMI could have contributed to this discrepancy in results. Therefore, additional studies are warranted to confirm our findings [9, 27, 30].

Although the effect of BMI on GE has been demonstrated in several studies, the results remain controversial. In the present study, GE was negatively correlated with BMI \( (r = -0.232) \) which is consistent with the results reported by Kautzky-Willer et al. and Lopes et al. [13, 33] but not with those reported by Healy et al. [14]. By conducting the FSIGT for measuring GE in white and African Americans, Healy et al. showed that no correlation was present in individuals with prediabetes. Plausible explanations for these inconsistent results include different ethnic populations, inclusion criteria, GE estimation methods, and the BMI (37.8 ± 6.3 kg/m\(^2\)) and young age (46.5 ± 11.2 years). In particularly, very few Chinese individuals have a comparable BMI.

IR is likely the key factor explaining the relationship between BMI and GE. According to the aforementioned discussion, the positive correlation between BMI and IR is confirmed [27]. Furthermore, the results of our studies and Lopez et al. all indicate that IR is negatively correlated with GE \( (r = -0.462, p < 0.001, \text{ and } r = -0.69, p < 0.001, \text{ respectively}) \) [13]. Therefore, through IR, BMI is associated with GE. From a physiological perspective, substantial evidence also supports our results. Obese individuals have higher IR and serum free fatty acids [34, 35]. Hawkins et al. showed that increased free fatty acid levels can deteriorate GE in T2DM [34, 35].

The risk, pathophysiology, and complications of T2DM differ between men and women [36]. For instance, compared with men, women with diabetes tend to be older and have a higher BMI [36–38]. The present study also investigated the differences in the aforementioned relationships between men and women. Our initial analysis results demonstrate that both men and women have similar \( r \) values derived from a simple correlation (Table 3). To further determine the relative contributions of BMI to the DFs, we transformed the absolute units to relative units (% changes) to compare the four slopes. Notably, after the transformation, the relationships became different. In women, BMI has the most profound influence on IR, followed by FPIS, SPIS, and GE. In men, the order changed to SPIS, IR, FPIS, and GE. These observations were comparable with those reported in the study by Kautzky-Willer et al., in which the association of BMI with \( \beta \)-cell function was sex-biased [39]. They revealed that although the slopes of IR and BMI were similar in both men and women, ISEC had a steeper increase in men than in women, indicating that men have a higher compensation capacity in response to IR than women [39]. This phenomenon can also be explained by differences in sex hormones, body fat composition, body fat distribution, and adipocytokines [36, 39].
The current study has some limitations. First, this is a cross-sectional study. Therefore, our data are less persuasive than those of a longitudinal study. Second, family history of T2DM, which is also a key factor for future diabetes development, was not evaluated in our established equations. The inclusion of this factor in the equations might increase the accuracy of our factor measurements. Third, only Chinese individuals were enrolled in our study; therefore, our study results should be applied with caution to other ethnic groups.

In conclusion, in men, BMI has the most profound effect on ISEC; however, in women, IR is the most important DF. Although GE is least correlated with BMI, it is still significant. Therefore, the role of GE should not be overlooked in this homogeneous cohort with the same age and FPG level.

Supporting information
S1 File. (XLS)

Acknowledgments
The authors thank all individuals who participated in the study. We acknowledge Wallace Academic Editing for editing this manuscript.

Author Contributions
Data curation: Chun-Hsien Hsu, Dee Pei.
Formal analysis: Chun-Hsien Hsu, Chang-Hsun Hsieh, Yao-Jen Liang.
Funding acquisition: Jiunn-Diann Lin.
Supervision: Yao-Jen Liang.
Writing – original draft: Jiunn-Diann Lin.
Writing – review & editing: Jiunn-Diann Lin, Chung-Ze Wu, An-Tsz Hsieh, Yen-Lin Chen, Dee Pei, Jin-Biou Chang.

References
1. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology 237: E214–223. https://doi.org/10.1152/ajpendo.1979.237.3.E214 PMID: 382871
2. Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46: 3–19. https://doi.org/10.1007/s00125-002-1009-0 PMID: 12637977
3. Polonsky KS, Sturis J, Bell GI (1996) Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance. The New England Journal of Medicine 334: 777–783. https://doi.org/10.1056/NEJM199603213341207 PMID: 8692553
4. Caumo A, Luzi L (2004) First-phase insulin secretion: does it exist in real life? Considerations on shape and function. Am J Physiol Endocrinol Metab 287: E371–385. https://doi.org/10.1152/ajpendo.00139.2003 PMID: 15308473
5. Pratley RE, Weyer C (2001) The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 44: 929–945. https://doi.org/10.1007/s001250100580 PMID: 11484070
6. Best JD, Kahn SE, Ader M, Watanabe RM, Ni TC, Bergman RN (1996) Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 19: 1018–1030. PMID: 8675104
7. Basu A, Caumo A, Bettini F, Gelsio A, Alzaid A, Cobelli C, et al. (1997) Impaired basal glucose effectiveness in NIDDM: contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol. Diabetes 46: 421–432. PMID: 9032098

8. Chiu KC, Cohan P, Lee NP, Chuang LM (2000) Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function. Diabetes Care 23: 1353–1358. PMID: 10977032

9. Chiu KC, Chuang LM, Yoon C (2001) Comparison of measured and estimated indices of insulin sensitivity and beta cell function: impact of ethnicity on insulin sensitivity and beta cell function in glucose-tolerant and normotensive subjects. J Clin Endocrinol Metab 86: 1620–1625. https://doi.org/10.1210/jcem.86.4.7432 PMID: 11297594

10. Lin JD, Chang JB, Wu CZ, Pei D, Hsieh AT, et al. (2014) Identification of insulin resistance in subjects with normal glucose tolerance. Ann Acad Med Singapore 43: 113–119. PMID: 24652432

11. Schuster DP, Kien CL, Osei K (1998) Differential impact of obesity on glucose metabolism in black and white American adolescents. Am J Med Sci 316: 361–367. PMID: 9856689

12. Polonsky KS, Given BD, Van Cauter E (1988) Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81: 442–448. https://doi.org/10.1172/JCI113339 PMID: 3276730

13. Lopez X, Bouche C, Tatro E, Goldfine AB (2009) Family history of diabetes impacts on interactions between minimal model estimates of insulin sensitivity and glucose effectiveness. Diabetes Obes Metab 11: 123–130. https://doi.org/10.1111/j.1463-1326.2008.00913.x PMID: 18518893

14. Healy SJ, Osei K, Gaillard T (2015) Comparative study of glucose homeostasis, lipids and lipoproteins, HDL functionality, and cardiometabolic parameters in modestly severely obese African Americans and White Americans with prediabetes: implications for the metabolic paradoxes. Diabetes Care 38: 228–235. https://doi.org/10.2337/dc14-1803 PMID: 25524949

15. Wang SL, Pan WH, Hwu CM, Ho LT, Lo CH, Lin SL, et al. (1997) Incidence of NIDDM and the effects of BMI and diabetes factors. Am J Med 102: 5S–10S. PMID: 10915

16. Wu CZ, Lin JD, Hsia TL, Hsu CH, Hsieh AT, et al. (2014) Accurate method to estimate insulin resistance from multiple regression models using data of metabolic syndrome and oral glucose tolerance test. J Diabetes Invest 5: 290–296. https://doi.org/10.1111/jdi.12155 PMID: 24843777

17. Lin JD, Hsu CH, Liang YJ, Lin WC, Hsieh CH, Wu CZ, et al. (2015) The estimation of first-phase insulin secretion by using components of the metabolic syndrome in a Chinese population. Int J Endocrinol 2015: 675245. https://doi.org/10.1155/2015/675245 PMID: 25815010

18. Wang SL, Pan WH, Hwu CM, Ho LT, Lo CH, Lin SL, et al. (1997) Incidence of NIDDM and the effects of gender, obesity and hyperinsulinemia in Taiwan. Diabetologia 40: 1431–1438. https://doi.org/10.1007/s001250050846 PMID: 9447951

19. Wu CZ, Lin JD, Hsia TL, Hsu CH, Hsieh CH, Chang JB, et al. (2014) Accurate method to estimate insulin resistance from multiple regression models using data of metabolic syndrome and oral glucose tolerance test. J Diabetes Investig 5: 290–296. https://doi.org/10.1111/jdi.12155 PMID: 24843777

20. Lin JD, Hsu CH, Liang YJ, Lin WC, Hsieh CH, Wu CZ, et al. (2015) The estimation of first-phase insulin secretion by using components of the metabolic syndrome in a Chinese population. Int J Endocrinol 2015: 675245. https://doi.org/10.1155/2015/675245 PMID: 25815010

21. Lin YT, Wu CZ, Liang W.C., Hsu CH, Hsieh CH, Pei D, et al. (2015) Measuring second phase of insulin secretion by components of metabolic syndrome. International Journal of Diabetes and Clinical Diagnosis 2: 113–118.

22. Chen YL, Lee SF, Pei C, Pei D, Lee CH, He CT, et al. (2016) Predicting Glucose Effectiveness in Chinese Participants Using Routine Measurements. Metab Syndr Relat Disord 14: 386–390. https://doi.org/10.1089/met.2015.0136 PMID: 27461066

23. D’Eon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS (2005) Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J Biol Chem 280: 35983–35991. https://doi.org/10.1074/jbc.M50739200 PMID: 16109719

24. Gao H, Bryzgalova G, Hedman E, Khan A, Endicic S, Gustafsson JA, et al. (2006) Long-term administration of estradiol decreases expression of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice: a possible mechanism is through direct regulation of signal transducer and activator of transcription 3. Mol Endocrinol 20: 1287–1299. https://doi.org/10.1210/me.2006-0012 PMID: 16627594

25. Gao H, Bryzgalova G, Hedman E, Khan A, Endicic S, Gustafsson JA, et al. (2006) Long-term administration of estradiol decreases expression of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice: a possible mechanism is through direct regulation of signal transducer and activator of transcription 3. Mol Endocrinol 20: 1287–1299. https://doi.org/10.1210/me.2006-0012 PMID: 16627594

26. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES (2004) Relationship between insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53: 1195–1200. PMID: 15111486
27. Hanley AJ, Wagenknecht LE, D’Agostino RB Jr., Zinman B, Haffner SM (2003) Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 52: 2740–2747. PMID: 14578292

28. van Haeften TW, Pimenta W, Mitrukou A, Korytkowski M, Jenssen T, Yki-Jarvinen H, et al. (2000) Relative contributions of beta-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism 49: 1318–1325. PMID: 11079822

29. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU (1985) Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Survey and Synthesis of Pathology Research 4: 110–125. PMID: 3901180

30. van Haeften TW, Dubbeldam S, Zonderland ML, Erkels DW (1998) Insulin secretion in normal glucose-tolerant relatives of type 2 diabetic subjects. Assessments using hyperglycemic glucose clamps and oral glucose tolerance tests. Diabetes Care 21: 278–282. PMID: 9539996

31. Moller JB, Dalla Man C, Overgaard RV, Ingwersen SH, Tomoe CW, Pedersen M, et al. (2014) Ethnic differences in insulin sensitivity, beta-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysis. J Clin Endocrinol Metab 99: 4273–4280. https://doi.org/10.1210/jc.2014-1724 PMID: 25119313

32. van Haeften TW, Pimenta W, Mitrukou A, Korytkowski M, Jenssen T, Yki-Jarvinen H, et al. (2002) Disturbances in beta-cell function in impaired fasting glycemia. Diabetes 51 Suppl 1: S265–270.

33. Kautzky-Willer A, Pacini G, Ludvik B, Schernthaner G, Prager R (1992) Beta-cell hypersecretion and not reduced hepatic insulin extraction is the main cause of hyperinsulinemia in obese nondiabetic subjects. Metabolism 41: 1304–1312. PMID: 1461136

34. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97: 2859–2865. https://doi.org/10.1172/JCI118742 PMID: 8675698

35. Hawkins M, Tonelli J, Kishore P, Stein D, Ragucci E, Gitig A, et al. (2003) Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes. Diabetes 52: 2748–2758. PMID: 14578293

36. Kautzky-Willer A, Harreiter J, Pacini G (2016) Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev 37: 278–316. https://doi.org/10.1210/er.2015-1137 PMID: 27159875

37. Wandell PE, Carlson AC (2014) Gender differences and time trends in incidence and prevalence of type 2 diabetes in Sweden—a model explaining the diabetes epidemic worldwide today? Diabetes Res Clin Pract 106: e90–92. https://doi.org/10.1016/j.diabres.2014.09.013 PMID: 25451899

38. Bray GA (2004) Medical consequences of obesity. J Clin Endocrinol Metab 89: 2583–2589. https://doi.org/10.1210/jc.2004-0535 PMID: 15181027

39. Kautzky-Willer A, Brazzale AR, Moro E, Vrbikova J, Bendova B, Sbrignadello S, et al. (2012) Influence of increasing BMI on insulin sensitivity and secretion in normotolerant men and women of a wide age span. Obesity (Silver Spring) 20: 1966–1973.